Abstract
Long-term treatment with celiprolol, a new cardioselective β blocker, significantly reduced blood pressure in 14 patients with essential hypertension (World Health Organization stages I to II). Heart rates remained within the normal range throughout treatment and no significant side effects were observed. In 4 patients, end-systolic septum thickness was measured, and evidence was obtained that the extent of left ventricular hypertrophy was reduced. These findings indicate that celiprolol can be used for the successful long-term treatment of essential hypertension, and that such treatment reduces left ventricular hypertrophy induced by high blood pressure.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
